This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
Cell Death & Disease Open Access 15 January 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. Kinase inhibitors overachieve in CLL. Nat Rev Drug Discov 13, 162–164 (2014). https://doi.org/10.1038/nrd4259
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4259
This article is cited by
-
The emerging role of mass spectrometry-based proteomics in drug discovery
Nature Reviews Drug Discovery (2022)
-
Staurosporine: new lease of life for parent compound of today’s novel and highly successful anti-cancer drugs
The Journal of Antibiotics (2018)
-
Molecular Genetics of the PI3K-AKT-mTOR Pathway in Genodermatoses: Diagnostic Implications and Treatment Opportunities
Journal of Investigative Dermatology (2016)
-
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
Cell Death & Disease (2015)